

1. Stubblefield MD, O'Dell MW. *Cancer Rehabilitation Principles and Practice*. New York: Demos Medical Publishers; 2009.
2. Cancer Facts & Figures 2013. American Cancer Society Web site. <http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013>. Accessed on (date).
3. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. *J Natl Cancer Inst* 2011;103:117-128.
4. National Spinal Cord Injury Statistical Center. Spinal cord injury facts and figures at a glance. *J Spinal Cord Med* 2013; 36:394-395.
5. PM&R Programs. Fellowship Programs. Association of Academic Physiatrists Web site. [http://www.physiatry.org/?page=fellowship\\_programs](http://www.physiatry.org/?page=fellowship_programs). Accessed on (date).
6. Sharp L, Vernino S. Paraneoplastic neuromuscular disorders. *Muscle Nerve* 2012;46:841-850.
7. Gulleit N, Rossi P, Kucuk O, et al. Cancer-induced cachexia: a guide for the oncologist. *J Soc Integr Oncol* 2009;7:155-169.
8. Lumachi F, Brunello A, Roma A, et al. Cancer-induced hypercalcemia. *Anticancer Res* 2009;29:1551-1555.
9. Bertagna X, Guignat L, Groussin L, et al. Cushing's disease. *Best Pract Res Clin Endocrinol Metab* 2009;23:607-623.
10. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. *Blood* 2007;110:1723-1729.
11. Toothaker TB, Rubin M. Paraneoplastic neurological syndromes: a review. *Neurologist* 2009;15:21-33.
12. Hauer-Jensen M, Fink LM, Wang J. Radiation injury and the protein C pathway. *Crit Care Med* 2004;32:S325-S330.
13. Stubblefield MD. Radiation fibrosis syndrome: neuromuscular and musculoskeletal complications in cancer survivors. *PM R* 2011;3:1041-1054.
14. Clinical Practice Guidelines in Oncology. Venous thromboembolic disease V.1.2010. National Comprehensive Cancer Network Web site. <http://www.nccn.org>. Accessed on (date).
15. Kelly BM, Yoder BM, Tang CT, et al. Venous thromboembolic events in the rehabilitation setting. *PM R* 2010;2:647-663.
16. Partsch H. Bed rest versus ambulation in the initial treatment of patients with proximal deep vein thrombosis. *Curr Opin Pulmonary Med* 2002;8:389-393.
17. Kiser TS, Stefans VA. Pulmonary embolism in rehabilitation patients: relation to time before return to physical therapy after diagnosis of deep vein thrombosis. *Arch Phys Med Rehabil* 1997;78:942-945.
18. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. *N Engl J Med* 1996;334:682-687.
19. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *N Engl J Med* 1996;334:677-681.
20. Partsch H, Kechavarz B, Kohn H, et al. The effect of mobilisation of patients during treatment of thromboembolic disorders with low-molecular-weight heparin. *Int Angiol* 1997;16:189-192.
21. Schellong SM, Schwarz T, Kropp J, et al. Bed rest in deep vein thrombosis and the incidence of scintigraphic pulmonary embolism. *Thromb Haemost* 1999;82:127-129.
22. Partsch H, Blattler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. *J Vasc Surg* 2000;32:861-869.
23. Aschwanden M, Labs KH, Engel H, et al. Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism. *Thromb Haemost* 2001;85:42-46.
24. Partsch H. Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation. *Vasa* 2001;30:195-204.
25. Junger M, Diehm C, Storiko H, et al. Mobilization versus immobilization in the treatment of acute proximal deep venous thrombosis: a prospective, randomized, open, multicentre trial. *Curr Med Res Opin* 2006;22:593-602.
26. Aldrich D, Hunt DP. When can the patient with deep venous thrombosis begin to ambulate? *Phys Ther* 2004;84:268-273.
27. Partsch H. Immediate ambulation and leg compression in the treatment of deep vein thrombosis. *Dis Mon* 2005;51:135-140.
28. Partsch H. Ambulation and compression after deep vein thrombosis: dispelling myths. *Semin Vasc Surg* 2005;18:148-152.
29. Kahn SR, Shrier I, Kearon C. Physical activity in patients with deep venous thrombosis: a systematic review. *Thromb Res* 2008;122:763-773.
30. Gay V, Hamilton R, Heiskell S, et al. Influence of bedrest or ambulation in the clinical treatment of acute deep vein thrombosis on patient outcomes: a review and synthesis of the literature. *Medsurg Nurs* 2009;18:293-299.
31. Aissaoui N, Martins E, Mouly S, et al. A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both. *Int J Cardiol* 2009;137:37-41.
32. Joffe HV, Kucher N, Tapson VF, et al. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. *Circulation* 2004;110:1605-1611.
33. Joffe HV, Goldhaber SZ. Upper-extremity deep vein thrombosis. *Circulation* 2002;106:1874-1880.
34. Custodio CM. Neuromuscular complications of cancer and cancer treatments. *Phys Med Rehabil Clin N Am* 2008;19:27-45.
35. Greenberg E, Treger I, Ring H. Rehabilitation outcomes in patients with brain tumors and acute stroke - Comparative study of inpatient rehabilitation. *Am J Phys Med Rehabil* 2006;85:568-573.
36. O'Dell MW, Barr K, Spanier D, et al. Functional outcome of inpatient rehabilitation in persons with brain tumors. *Arch Phys Med Rehabil* 1998;79:1530-1534.
37. Mukand JA, Blackinton DD, Crincoli MG, et al. Incidence of neurologic deficits and rehabilitation of patients with brain tumors. *Am J Phys Med Rehabil* 2001;80:346-350.
38. Geler-Kulcu D, Gulsen G, Buyukbaba E, et al. Functional recovery of patients with brain tumor or acute stroke after rehabilitation: A comparative study. *J Clin Neurosci* 2009;16:74-78.
39. Huang ME, Wartella JE, Kreutzer JS. Functional outcomes and quality of life in patients with brain tumors: A preliminary report. *Arch Phys Med Rehabil* 2001;82:1540-1546.
40. Kirshblum S, O'Dell MW, Ho C, et al. Rehabilitation of persons with central nervous system tumors. *Cancer* 2001;92:1029-1038.
41. Parsch D, Mikut R, Abel R. Postacute management of patients with spinal cord injury due to metastatic tumour disease: survival and efficacy of rehabilitation. *Spinal Cord* 2003;41:205-210.
42. Stubblefield MD, Bilsky MH. Barriers to rehabilitation of the neurosurgical spine cancer patient. *J Surg Oncol* 2007;95:419-426.
43. Wang JC, Boland P, Mitra N, et al. Single-stage posterolateral transpedicular approach for resection of epidural metastatic spine tumors involving the vertebral body with circumferential reconstruction: results in 140 patients. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. *J Neurosurg Spine* 2004;1:287-298.
44. Guo Y, Young B, Palmer JL, et al. Prognostic factors for survival in metastatic spinal cord compression: a retrospective study in a rehabilitation setting. *Am J Phys Med Rehabil* 2003;82:665-668.
45. Ecker RD, Endo T, Wetjen NM, Krauss WE. Diagnosis and treatment of vertebral column metastases. *Mayo Clin Proc* 2005;80:1177-1186.
46. DeAngelis LM, Boutsos D. Leptomeningeal metastasis. *Cancer Invest* 2005;23:145-154.
47. Wuemser LA, Ho CH, Chiodo AE, et al. Spinal cord injury medicine. 2. Acute care management of traumatic and nontraumatic injury. *Arch Phys Med Rehabil* 2007;88:S55-S61.
48. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126:338S-400S.
49. McKinley WO, Conti-Wyneken AR, Vokac CW, et al. Rehabilitative functional outcome of patients with neoplastic spinal cord compressions. *Arch Phys Med Rehabil* 1996;77:892-895.
50. New PW, Rawicki HB, Bailey MJ. Nontraumatic spinal cord injury: demographic characteristics and complications. *Arch Phys Med Rehabil* 2002;83:996-1001.
51. Tarulli AW, Raynor EM. Lumbosacral radiculopathy. *Neurol Clin* 2007;25:387-405.
52. Radhakrishnan K, Litchy WJ, O'Fallon WM, et al. Epidemiology of cervical radiculopathy. A population-based study from Rochester, Minnesota, 1976 through 1990. *Brain* 1994;117:325-335.
53. Ciol MA, Deyo RA, Howell E, et al. An assessment of surgery for spinal stenosis: Time trends, geographic variations, complications, and reoperations. *J Am Geriatr Soc* 1996;44:285-290.
54. Posner JB. *Neurologic Complications of Cancer*. Philadelphia: F.A. Davis Company; 1995.
55. Chamberlain MC. Neurotoxicity of cancer treatment. *Curr Oncol Rep* 2010;12:60-67.
56. Gilden D, Cohrs RJ, Mahalingam R, et al. Neurological disease produced by Varicella zoster virus reactivation without rash. *Curr Top Microbiol Immunol* 2010;342:243-253.
57. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. *Clin Infect Dis* 2007;44:S1-S26.
58. Hsia AW, Katz JS, Hancock SL, et al. Post-irradiation polyradiculopathy mimics leptomeningeal tumor on MRI. *Neurology* 2003;60:1694-1696.
59. Greenfield MM, Stark FM. Post-irradiation neuropathy. *Am J Roentgenol Radium Ther* 1948;60:617-622.
60. Maier JC, Perry RH, Saylor W, et al. Radiation myelitis of the dorsolumbar spinal cord. *Radiology* 1969;93:153-160.
61. Kristensen O, Melgard B, Schiodt AV. Radiation myelopathy of the lumbosacral spinal cord. *Acta Neurol Scand* 1977;56:217-222.
62. Berlit P, Schweddeheimer K. Neuropathological findings in radiation myelopathy of the lumbosacral cord. *Eur Neurol* 1987;27:29-34.
63. Lamy C, Mas JL, Varet B, et al. Post-radiation lower motor neuron syndrome presenting as monomelic amyotrophy. *J Neurol Neurosurg Psychiatry* 1991;54:648-649.
64. Bowen J, Gregory R, Squier M, et al. The post-irradiation lower motor neuron syndrome: neuropathy or radiculopathy? *Brain* 1996;119:1429-1439.

65. Stubblefield MD, Slovin S, MacGregor-Cortelli B, et al. An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. *Clin Oncol (R Coll Radiol)* 2006;18:410–418.
66. Stubblefield MD, McNeely ML, Alfano CM, et al. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy. *Cancer* 2012;118:2250–2260.
67. Dropcho EJ. Remote neurologic manifestations of cancer. *Neurol Clin* 2002;20:85–122.
68. Jaeckle KA. Neurological manifestations of neoplastic and radiation-induced plexopathies. *Semin Neurol* 2004;24:385–393.
69. Pourmand R. *Neuromuscular Diseases: Expert Clinicians' Views*. Boston: Butterworth-Heinemann; 2001.
70. Lusk MD, Kline DG, Garcia CA. Tumors of the brachial plexus. *Neurosurgery* 1987;21:439–453.
71. Donner TR, Voorhies RM, Kline DG. Neural sheath tumors of major nerves. *J Neurosurg* 1994;81:362–373.
72. Ganju A, Roosen N, Kline DG, et al. Outcomes in a consecutive series of 111 surgically treated plexal tumors: a review of the experience at the Louisiana State University Health Sciences Center. *J Neurosurg* 2001;95:51–60.
73. Dropcho EJ. Neurotoxicity of radiation therapy. *Neurol Clin* 2010;28:217–234.
74. Galecki J, Hiczer-Grzenkowicz J, Grudzien-Kowalska M, et al. Radiation-induced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer—a review. *Acta Oncol* 2006;45:280–284.
75. Kori SH, Foley KM, Posner JB. Brachial plexus lesions in patients with cancer: 100 cases. *Neurology* 1981;31:45–50.
76. Sureka J, Cherian RA, Alexander M, et al. MRI of brachial plexopathies. *Clin Radiol* 2009;64:208–218.
77. Thomas JE, Colby MY Jr. Radiation-induced or metastatic brachial plexopathy? A diagnostic dilemma. *JAMA* 1972;222:1392–1395.
78. Ferrante MA. Brachial plexopathies: classification, causes, and consequences. *Muscle Nerve* 2004;30:547–568.
79. Sathasivam S, Lecky B, Manohar R, et al. Neuralgic amyotrophy. *J Bone Joint Surg Br* 2008;90:550–553.
80. Tracy JA, Dyck PJ. The spectrum of diabetic neuropathies. *Phys Med Rehabil Clin N Am* 2008;19:1–26.
81. Stubblefield MD, Burstein HJ, Burton AW, et al. NCCN task force report: management of neuropathy in cancer. *J Natl Compr Canc Netw* 2009;7: S1–S26.
82. Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. *Lancet Neurol* 2010;9:402–412.
83. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. *J Clin Oncol* 2006;24:1633–1642.
84. Umapathi T, Chaudhry V. Toxic neuropathy. *Curr Opin Neurol* 2005;18: 574–580.
85. Kocer B, Sucak G, Kuruoglu R, et al. Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy. *Acta Neurol Belg* 2009;109:120–126.
86. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. *J Neurol* 2002;249:9–17.
87. Lauria G, Pareyson D, Sghirlanzoni A. Neurophysiological diagnosis of acquired sensory ganglionopathies. *Eur Neurol* 2003;50:146–152.
88. Ramchandren S, Lewis RA. Monoclonal gammopathy and neuropathy. *Curr Opin Neurol* 2009;22:480–485.
89. Portlock CS, Boland P, Hays AP, et al. Nemaquine myopathy: a possible late complication of Hodgkin's disease therapy. *Hum Pathol* 2003;34:816–818.
90. Tuoheti Y, Okada K, Osanai T, et al. Skeletal muscle metastases of carcinoma: a clinicopathological study of 12 cases. *Jpn J Clin Oncol* 2004;34: 210–214.
91. Levin MI, Mozaffar T, Al-Lozi MT, et al. Paraneoplastic necrotizing myopathy: clinical and pathological features. *Neurology* 1998;50:764–767.
92. Briani C, Doria A, Sarzi-Puttini P, et al. Update on idiopathic inflammatory myopathies. *Autoimmunity* 2006;39:161–170.
93. Smestad C, Monstad P, Lindboe CF, et al. Amyloid myopathy presenting with distal atrophic weakness. *Muscle Nerve* 2004;29:605–609.
94. Friedman Y, Paul JT, Turley J, et al. Axial myopathy due to primary amyloidosis. *Muscle Nerve* 2007;36:542–546.
95. Walsh RJ, Amato AA. Toxic myopathies. *Neurol Clin* 2005;23:397–428.
96. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. *J Endocrinol* 2008;197:1–10.
97. Owczarek J, Jasinska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. *Pharmacol Rep* 2005;57:23–34.
98. Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. *Neurology* 1997;48:1234–1238.
99. Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. *J Neurol* 2001;248:929–934.
100. Stoll C, Bendszus M, Perez J, et al. Magnetic resonance imaging of the peripheral nervous system. *J Neurol* 2009;256:1043–1051.
101. van Es HW, Bollen TL, van Heeswijk HP. MRI of the brachial plexus: A pictorial review. *Eur J Radiol* 2010;74:391–402.
102. Huang JH, Johnson VE, Zager EL. Tumors of the peripheral nerves and plexuses. *Curr Treat Options Neurol* 2006;8:299–308.
103. England JD, Gronseth GS, Franklin G, et al. Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). *Muscle Nerve* 2009;39:116–125.
104. Stubblefield MD, Custodio CM. Upper-extremity pain disorders in breast cancer. *Arch Phys Med Rehabil* 2006;87:S96–S99.
105. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. *Br J Cancer* 1987;55:61–66.
106. Griessmann H, Schuttmeier W. Weitere Erfahrungen mit der Marknagelung nach Kuntscher an der Chirurgische Universitätsklinik Kiel. *Chirurg* 1947;17/18:316–333.
107. Bunting RW, Shea B. Bone metastasis and rehabilitation. *Cancer* 2001; 92:1020–1028.
108. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. *Clin Orthop Relat Res* 1989: 256–264.
109. Van der Linden YM, Dijkstra PD, Kroon HM, et al. Comparative analysis of risk factors for pathological fracture with femoral metastases. *J Bone Joint Surg Br* 2004;86:566–573.
110. Vargo M. Orthopedic management of malignant bone lesions. *PM&R State Art Rev* 1994;8:363–391.
111. Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. *Spine (Phila Pa 1976)* 2010;35:E1221–E1229.
112. Fourny DR, Frangou EM, Ryken TC, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. *J Clin Oncol* 2011;29:3072–3077.
113. Bilsky MH. New therapeutics in spine metastases. *Expert Rev Neurother* 2005;5:831–840.
114. Lauffer I, Rubin DG, Lis E, et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. *Oncologist* 2013;18:744–751.
115. Yarnold J, Brotons MC. Pathogenetic mechanisms in radiation fibrosis. *Radiother Oncol* 2010;97:149–161.
116. Libshitz HI, DuBrow RA, Loyer EM, et al. Radiation change in normal organs: an overview of body imaging. *Eur Radiol* 1996;6:786–795.
117. New P. Radiation injury to the nervous system. *Curr Opin Neurol* 2001; 14:725–734.
118. Johansson S, Svensson H, Denekamp J. Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. *Int J Radiat Oncol Biol Phys* 2002;52:1207–1219.
119. Stone HB, Coleman CN, Anscher MS, et al. Effects of radiation on normal tissue: consequences and mechanisms. *Lancet Oncol* 2003;4:529–536.
120. Falkmer U, Jarhult J, Wersall P, et al. A systematic overview of radiation therapy effects in skeletal metastases. *Acta Oncol* 2003;42:620–633.
121. Thompson CA, Mauck K, Haver R, et al. Care of the adult Hodgkin lymphoma survivor. *Am J Med* 2011;124:1106–1112.
122. Cross NE, Glantz MJ. Neurologic complications of radiation therapy. *Neurol Clin* 2003;21:249–277.
123. Pradat PF, Delanian S. Late radiation injury to peripheral nerves. *Handb Clin Neurol* 2013;115:743–758.
124. Miller TM, Layzer RB. Muscle cramps. *Muscle Nerve* 2005;32:431–442.
125. Gutmann L, Gutmann L. Myokymia and neuromyotonia 2004. *J Neurol* 2004;251:138–142.
126. Baxi SS, Matasar MJ. State-of-the-art issues in Hodgkin's lymphoma survivorship. *Curr Oncol Rep* 2010;12:366–373.
127. Jaeckle KA. Neurologic manifestations of neoplastic and radiation-induced plexopathies. *Semin Neurol* 2010;30:254–262.
128. Herrera JE, Stubblefield MD. Rotator cuff tendonitis in lymphedema: a retrospective case series. *Arch Phys Med Rehabil* 2004;85:1939–1942.
129. Dijkstra PU, van Wilgen PC, Buijs RP, et al. Incidence of shoulder pain after neck dissection: a clinical explorative study for risk factors. *Head Neck* 2001;23:947–953.
130. Robbins KT, Clayman G, Levine PA, et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. *Arch Otolaryngol Head Neck Surg* 2002;128:751–758.
131. Speksnijder CM, van der Bilt A, Slapendel M, et al. Neck and shoulder function in patients treated for oral malignancies: a 1-year prospective cohort study. *Head Neck* 2013;35:1303–1313.
132. McNeely ML, Parliament M, Courmeya KS, et al. A pilot study of a randomized controlled trial to evaluate the effects of progressive resistance exercise training on shoulder dysfunction caused by spinal accessory neurectomy in head and neck cancer survivors. *Head Neck* 2004;26: 518–530.
133. McNeely ML, Parliament MB, Seikaly H, et al. Effect of exercise on upper extremity pain and dysfunction in head and neck cancer survivors: a randomized controlled trial. *Cancer* 2008;113:214–222.
134. Lauchlan DT, McCaul JA, McCarron T, et al. An exploratory trial of preventative rehabilitation on shoulder disability and quality of life in patients following neck dissection surgery. *Eur J Cancer Care (Engl)* 2011;20: 113–122.
135. Carvalho AP, Vital FM, Soares BC. Exercise interventions for shoulder dysfunction in patients treated for head and neck cancer. *Cochrane Database Syst Rev* 2012;4:CD008693.

136. Dijkstra PU, Kalk WW, Roodenburg JL. Trismus in head and neck oncology: a systematic review. *Oral Oncol* 2004;40:879–889.
137. Tveteras K, Kristensen S. The aetiology and pathogenesis of trismus. *Clin Otolaryngol Allied Sci* 1986;11:383–387.
138. Dijkstra PU, Huisman PM, Roodenburg JL. Criteria for trismus in head and neck oncology. *Int J Oral Maxillofac Surg* 2006;35:337–342.
139. Ichimura K, Tanaka T. Trismus in patients with malignant tumours in the head and neck. *J Laryngol Otol* 1993;107:1017–1020.
140. Louise Kent M, Brennan MT, Noll JL, et al. Radiation-induced trismus in head and neck cancer patients. *Support Care Cancer* 2008;16:305–309.
141. Wang CJ, Huang EY, Hsu HC, et al. The degree and time-course assessment of radiation-induced trismus occurring after radiotherapy for nasopharyngeal cancer. *Laryngoscope* 2005;115:1458–1460.
142. Teguh DN, Levendag PC, Voet P, et al. Trismus in patients with oropharyngeal cancer: relationship with dose in structures of mastication apparatus. *Head Neck* 2008;30:622–630.
143. Goldstein M, Maxymiw WC, Cummings BJ, et al. The effects of antitumor irradiation on mandibular opening and mobility: a prospective study of 58 patients. *Oral Surg Oral Med Oral Pathol Radiol Endod* 1999;88:365–373.
144. Dhanrajani PJ, Jonaidel O. Trismus: aetiology, differential diagnosis and treatment. *Dent Update* 2002;29:88–92.
145. Dijkstra PU, Sterken MW, Pater R, et al. Exercise therapy for trismus in head and neck cancer. *Oral Oncol* 2007;43:389–394.
146. Grandi G, Silva ML, Streit C, et al. A mobilization regimen to prevent mandibular hypomobility in irradiated patients: an analysis and comparison of two techniques. *Med Oral Patol Oral Cir Bucal* 2007;12:E105–E109.
147. Buchbinder D, Curriwan RB, Kaplan AJ, et al. Mobilization regimens for the prevention of jaw hypomobility in the irradiated patient: a comparison of three techniques. *J Oral Maxillofac Surg* 1993;51:863–867.
148. Tang Y, Shen Q, Wang Y, et al. A randomized prospective study of rehabilitation therapy in the treatment of radiation-induced dysphagia and trismus. *Strahlenther Onkol* 2011;187:39–44.
149. King GE, Scheetz J, Jacob RF, et al. Electrotherapy and hyperbaric oxygen: promising treatments for postradiation complications. *J Prosthet Dent* 1989;62:331–334.
150. Chua DT, Lo C, Yuen J, et al. A pilot study of pentoxifylline in the treatment of radiation-induced trismus. *Am J Clin Oncol* 2001;24:366–369.
151. Bhrary AD, Izzard M, Wood AJ, Futran ND. Coronoidectomy for the treatment of trismus in head and neck cancer patients. *Laryngoscope* 2007;117:1952–1956.
152. Stubblefield MD, Levine A, Custodio CM, et al. The role of botulinum toxin type A in the radiation fibrosis syndrome: a preliminary report. *Arch Phys Med Rehabil* 2008;89:417–421.
153. Hartl DM, Cohen M, Julieron M, et al. Botulinum toxin for radiation-induced facial pain and trismus. *Otolaryngol Head Neck Surg* 2008;138:459–463.
154. Cousins N, MacAulay F, Lang H, et al. A systematic review of interventions for eating and drinking problems following treatment for head and neck cancer suggests a need to look beyond swallowing and trismus. *Oral Oncol* 2013;49:387–400.
155. Cohen EG, Deschler DG, Walsh K, et al. Early use of a mechanical stretching device to improve mandibular mobility after composite resection: a pilot study. *Arch Phys Med Rehabil* 2005;86:1416–1419.
156. Kamstra JJ, Roodenburg JL, Beurskens CH, et al. TheraBite exercises to treat trismus secondary to head and neck cancer. *Support Care Cancer* 2013;21:951–957.
157. Lubit EC. The trismus exerciser. An oral dynamic bite opener. *N Y State Dent J* 1968;34:489–493.
158. Brown KE. Dynamic opening device for mandibular trismus. *J Prosthet Dent* 1968;20:438–442.
159. Kouyoumdjian JH, Chalian VA, Hutton C. An intraoral positive-pressure device for treatment of trismus. *Oral Surg Oral Med Oral Pathol* 1986;61:456–458.
160. Dijkstra PU, Kropmans TJ, Tamminga RY. Modified use of a dynamic bite opener—treatment and prevention of trismus in a child with head and neck cancer: a case report. *Cranio* 1992;10:327–329.
161. Brunello DL, Mandikos MN. The use of a dynamic opening device in the treatment of radiation induced trismus. *Aust Prosthodont J* 1995;9:45–48.
162. Lo LJ, Lin CL, Chen YR. A device for temporomandibular joint exercise and trismus correction: design and clinical application. *J Plast Reconstr Aesthet Surg* 2008;61:297–301.
163. Shulman DH, Shipman B, Willis FB. Treating trismus with dynamic splinting: a cohort, case series. *Adv Ther* 2008;25:9–16.
164. Stubblefield MD, Manfield L, Riedel ER. A preliminary report on the efficacy of a dynamic jaw opening device (dynamaplast trismus system) as part of the multimodal treatment of trismus in patients with head and neck cancer. *Arch Phys Med Rehabil* 2010;91:1278–1282.
165. Usuba M, Akai M, Shirasaki Y, et al. Experimental joint contracture correction with low torque—long duration repeated stretching. *Clin Orthop Relat Res* 2007;456:70–78.
166. Astudillo L, Hollington L, Game X, et al. Cervical dystonia mimicking dropped-head syndrome after radiotherapy for laryngeal carcinoma. *Clin Neurol Neurosurg* 2003;106:41–43.
167. Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for cervical dystonia. *Cochrane Database Syst Rev* 2005;CD003633.
168. DiSipio T, Rye S, Newman B, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. *Lancet Oncol* 2013;14:500–515.
169. Shah C, Arthur D, Riutta J, et al. Breast-cancer related lymphedema: a review of procedure-specific incidence rates, clinical assessment AIDS, treatment paradigms, and risk reduction. *Breast J* 2012;18:357–361.
170. Braddom RL, ed. *Physical Medicine and Rehabilitation*. 3rd ed. Philadelphia: WB Saunders Company; 2007.
171. Sadeghi R, Kazemzadeh C, Keshtgar M. Diagnostic application of lymphoscintigraphy in the management of lymphoedema. *Hell J Nucl Med* 2010;13:6–10.
172. Cheville AL, McGarvey CL, Petrek JA, et al. Lymphedema management. *Semin Radiat Oncol* 2003;13:290–301.
173. Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. *Ann Surg Oncol* 2006;13:491–500.
174. Graham PH. Compression prophylaxis may increase the potential for flight-associated lymphoedema after breast cancer treatment. *Breast* 2002;11:66–71.
175. Paskett ED, Dean JA, Oliveri JM, et al. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. *J Clin Oncol* 2012;30:3726–3733.
176. Badger CM, Peacock JL, Mortimer PS. A randomized, controlled, parallel-group clinical trial comparing multilayer bandaging followed by hosiery versus hosiery alone in the treatment of patients with lymphedema of the limb. *Cancer* 2000;88:2832–2837.
177. Carati CJ, Anderson SN, Gannon BJ, et al. Treatment of postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-controlled trial. *Cancer* 2003;98:1114–1122.
178. Ahmed Omar MT, Abd-El-Gayed Ebid A, El Morsy AM. Treatment of post-mastectomy lymphedema with laser therapy: double blind placebo control randomized study. *J Surg Res* 2011;165:82–90.
179. Loprinzi CL, Kugler JW, Sloan JA, et al. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. *N Engl J Med* 1999;340:346–350.
180. Pecking AP, Fevrier B, Wargon C, et al. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). *Angiology* 1997;48:93–98.
181. Mehrara BJ, Zampell JC, Suami H, et al. Surgical management of lymphedema: past, present, and future. *Lymphatic Res Biol* 2011;9:159–167.
182. Ahmed RL, Thomas W, Yee D, et al. Randomized controlled trial of weight training and lymphedema in breast cancer survivors. *J Clin Oncol* 2006;24:2765–2772.
183. Sagen A, Karesen R, Risberg MA. Physical activity for the affected limb and arm lymphedema after breast cancer surgery. A prospective, randomized controlled trial with two years follow-up. *Acta Oncol* 2009;48:1102–1110.
184. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-cancer-related lymphedema. *N Engl J Med* 2009;361:664–673.
185. Schmitz KH, Ahmed RL, Troxel AB, et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. *JAMA* 2010;304:2699–2705.
186. Kwan ML, Cohn JC, Armer JM, et al. Exercise in patients with lymphedema: a systematic review of the contemporary literature. *J Cancer Surviv* 2011;5:320–336.
187. Knols R, Aaronson NK, Uebelhart D, et al. Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. *J Clin Oncol* 2005;23:3830–3842.
188. McNeely ML, Campbell KL, Rowe BH, et al. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. *CMAJ* 2006;175:34–41.
189. Craft LL, Vaniterson EH, Helenowski IB, et al. Exercise effects on depressive symptoms in cancer survivors: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2012;21:3–19.
190. Fong DY, Ho JW, Hui BP, et al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. *BMJ* 2012;344:e70.
191. Jones LW, Alfano CM. Exercise-oncology research: past, present, and future. *Acta Oncol* 2013;52:195–215.
192. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. *Med Sci Sports Exerc* 2010;42:1409–1426.
193. Fairey AS, Courneya KS, Field CJ, et al. Physical exercise and immune system function in cancer survivors: a comprehensive review and future directions. *Cancer* 2002;94:539–551.
194. Jones LW, Courneya KS, Fairey AS, et al. Effects of an oncologist's recommendation to exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: a single-blind, randomized controlled trial. *Ann Behav Med* 2004;28:105–113.
195. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 2003;348:1625–1638.
196. Johansson K, Ohlsson K, Ingvar C, et al. Factors associated with the development of arm lymphedema following breast cancer treatment: a match pair case-control study. *Lymphology* 2002;35:59–71.

197. Campos MP, Hassan BJ, Riechelmann R, et al. Cancer-related fatigue: a practical review. *Ann Oncol* 2011;22:1273–1279.
198. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. *Cochrane Database Syst Rev* 2012;11:CD006145.
199. Minton O, Richardson A, Sharpe M, et al. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. *J Pain Symptom Manage* 2011;41:761–767.
200. Allen RJ. Physical agents used in the management of chronic pain by physical therapists. *Phys Med Rehabil Clin N Am* 2006;17:315–345.
201. Sicard-Rosenbaum L, Danoff J. Cancer and ultrasound: a warning. *Phys Ther* 1993;73:404–406.
202. Sicard-Rosenbaum L, Lord D, Danoff JV, et al. Effects of continuous therapeutic ultrasound on growth and metastasis of subcutaneous murine tumors. *Phys Ther* 1995;75:3–11.
203. Sicard-Rosenbaum L, Danoff JV, Guthrie JA, et al. Effects of energy-matched pulsed and continuous ultrasound on tumor growth in mice. *Phys Ther* 1998;78:271–277.
204. Robertson VJ, Ward AR. Dangers in extrapolating in vitro uses of therapeutic ultrasound. *Phys Ther* 1996;76:78–79.
205. Chapman BL, Liebert RB, Lininger MR, et al. An introduction to physical therapy modalities. *Adolesc Med State Art Rev* 2007;18:11–23.
206. Carroll D, Moore RA, McQuay HJ, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. *Cochrane Database Syst Rev* 2001:CD003222.
207. Walsh DM, Howe TE, Johnson MI, et al. Transcutaneous electrical nerve stimulation for acute pain. *Cochrane Database Syst Rev* 2009:CD006142.
208. Robb K, Oxberry SG, Bennett MI, et al. A cochrane systematic review of transcutaneous electrical nerve stimulation for cancer pain. *J Pain Symptom Manage* 2009;37:746–753.
209. Chevillat AL. Pain management in cancer rehabilitation. *Arch Phys Med Rehabil* 2001;82:S84–S87.
210. Nicolson SE, Caplan JP, Williams DE, et al. Comorbid pain, depression, and anxiety: multifaceted pathology allows for multifaceted treatment. *Harv Rev Psychiatry* 2009;17:407–420.
211. Tang MF, Liou TH, Lin CC. Improving sleep quality for cancer patients: benefits of a home-based exercise intervention. *Support Care Cancer* 2009;18:1329–1339.
212. Aggarwal VR, Tickle M, Javidi H, et al. Reviewing the evidence: can cognitive behavioral therapy improve outcomes for patients with chronic orofacial pain? *J Orofac Pain* 2010;24:163–171.
213. Griffith K, Wenzel J, Shang J, et al. Impact of a walking intervention on cardiorespiratory fitness, self-reported physical function, and pain in patients undergoing treatment for solid tumors. *Cancer* 2009;115:4874–4884.
214. Scott NA, Guo B, Barton PM, et al. Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review. *Pain Med* 2009;10:54–69.
215. Bannuru RR, Natov NS, Obadan IE, et al. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. *Arthritis Rheum* 2009;61:1704–1711.
216. Deng G, Cassileth BR, Yeung KS. Complementary therapies for cancer-related symptoms. *J Support Oncol* 2004;2:419–426.
217. Cassileth BR, Deng G. Complementary and alternative therapies for cancer. *Oncologist* 2004;9:80–89.